stereotactic ablative radiotherapy + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Oct 2023: Trial registered, NCT06084338
  2. 14 Dec 2023: Trial started, NCT06084338

The trials

NCT06084338: Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

State
Under way
Phase
Phase 2
People
60 planned
Started
14 Dec 2023
Primary completion
29 Nov 2027
Arms
Arm 1
Results
None posted
  1. 16 Oct 2023: Trial registered
  2. 14 Dec 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.